- Home
- MAIA
as 06-26-2025 10:38am EST
MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. THIO (6-thio-dG or 6-thio-2 '-deoxyguanosine), its lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. Patients with advanced NSCLC will be treated first with THIO followed a few days later by the immune checkpoint inhibitor Libtayo (cemiplimab), manufactured and commercialized by Regeneron.
| Founded: | 2018 | Country: | United States |
| Employees: | N/A | City: | CHICAGO |
| Market Cap: | 46.7M | IPO Year: | 2022 |
| Target Price: | N/A | AVG Volume (30 days): | 416.1K |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.80 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.40 - $4.24 | Next Earning Date: | 08-08-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of MAIA Biotechnology Inc. (MAIA)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Smith Stan | MAIA | Director | Jun 3 '25 | Buy | $1.50 | 33,333 | $49,999.50 | 1,305,059 | |
| Smith Stan | MAIA | Director | May 8 '25 | Buy | $1.50 | 66,666 | $99,999.00 | 1,305,059 | |
| Guerrero Ramiro | MAIA | Director | May 8 '25 | Buy | $1.50 | 20,000 | $30,000.00 | 588,218 |
Latest MAIA Biotechnology Inc. News
MAIA Breaking Stock News: Dive into MAIA Ticker-Specific Updates for Smart Investing
Business Wire
2 days ago
MAIA Biotechnology Welcomes Leading Hepatocellular Carcinoma Clinician-Scientists to Scientific Advisory Board
TipRanks
7 days ago
MAIA Biotechnology, Roche sign supply agreement for cancer therapies
MT Newswires
8 days ago
Maia Biotechnology Signs Clinical Supply Deal With Roche; Shares Rise
Business Wire
8 days ago
MAIA Biotechnology Announces Master Clinical Supply Agreement with Roche for Hard-to-Treat Cancer Therapies
Business Wire
16 days ago
MAIA Biotechnology to Present at BIO International Convention 2025
Benzinga
21 days ago
MAIA Biotechnology's Experimental Cancer Drug Shows Tripled Survival Vs. Standard Chemotherapy In Pretreated Lung Cancer Patients
Business Wire
21 days ago
MAIA Biotechnology Announces New Responder in Non-Small Cell Lung Cancer Phase 2 Clinical Trial
MT Newswires
21 days ago
Maia Biotechnology Says Ateganosine Treatment Extends Median Overall Survival in Lung Cancer Study
Compare MAIA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "MAIA MAIA Biotechnology Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.